Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
The Pharma Data
JUNE 15, 2025
Clinical Development Plans and Future Outlook Intellia’s ongoing Phase 3, randomized, double-blind, placebo-controlled HAELO trial is currently assessing the safety and efficacy of lonvo-z at the 50 mg dose in a larger patient population.
Let's personalize your content